Key Ideas

Peripheral T-cell lymphoma (PTCL) is rare, but the bigger problem isn't rarity, it's that an incomplete diagnostic workup doesn't produce an uncertain diagnosis, it produces a wrong one. Roughly a quarter of outside diagnoses are revised after expert hematopathology review, and getting this right (often requiring biopsy tissue itself, not just a report, sent for re-review) fundamentally changes treatment.

A Rare Diagnosis That Deserves a Complete Workup

T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference. There are more than 30 distinct mature T-cell lymphoma subtypes. Rarity itself isn't really the core problem; the core problem is that classification keeps evolving (angioimmunoblastic T-cell lymphoma, for example, is no longer its own standalone category, but is now classified as a form of nodal T follicular helper cell lymphoma) and that a limited diagnostic workup tends to produce a confidently wrong diagnosis rather than an appropriately uncertain one.

In an NCCN cohort of T-cell lymphomas referred for expert review, 24% of cases were discordant with the referring diagnosis — 36% among those referred with a final rather than provisional diagnosis. In nearly half of those discordant cases, the reclassification could have led to a different treatment strategy. The changes ran in both directions: several patients arrived with a diagnosis of B-cell lymphoma or classical Hodgkin lymphoma and turned out to have T-cell lymphoma, and a few referred with benign diagnoses were found to have lymphoma requiring treatment. In the International T-Cell Lymphoma Project, expert central review confirmed a T- or NK-cell lymphoma diagnosis in 88% of cases; the remainder proved to be Hodgkin lymphoma, B-cell lymphoma, unclassifiable lymphoma, or something other than lymphoma altogether. This is why expert hematopathology review matters so much, and why, when seeking a second opinion, sending the actual pathology blocks (not just the written report) is essential: with tissue in hand, a pathologist can perform the additional workup needed; with only a report, there's nothing more to do.

What a Complete Workup Actually Requires

A complete diagnostic workup includes attention to morphology and architecture (including specific growth patterns) and adequate tissue, ideally an excisional biopsy, or at minimum a core biopsy. Beyond that, a comprehensive immunophenotype panel (T-cell antigens, CD4, CD8, cytotoxic markers, CD30, CD56), assessment of T-cell receptor alpha-beta versus gamma-delta lineage (which defines an entirely distinct subset of T-cell lymphoma, and is often overlooked), and molecular studies — T-cell receptor gene rearrangement to confirm clonality, and next-generation sequencing to support certain diagnoses — round out the evaluation. HTLV-1 testing, while technically optional in NCCN guidelines, is something I perform on every patient I see, given its critical importance in diagnosing adult T-cell leukemia/lymphoma (ATLL) correctly, and EBV testing is likewise part of a complete workup.

A Case in Point: When "NOS" Actually Wasn't

Consider a patient with cervical lymphadenopathy, fatigue, weight loss, and fever, whose limited core biopsy showed atypical, CD4-predominant T cells with some loss of T-cell antigen expression, no CD30 aberrancy, and no cytotoxic phenotype, initially signed out as PTCL, not otherwise specified (NOS). Nothing on that initial workup was technically wrong, but it also wasn't complete. On expert review, the same tissue showed an expanded follicular dendritic cell meshwork, strong expression of multiple T follicular helper (TFH) markers alongside CD4, and molecular support for a TFH-derived process. The corrected diagnosis: nodal T-follicular helper cell lymphoma, angioimmunoblastic type — what was previously called angioimmunoblastic T-cell lymphoma — a genuinely distinct entity with its own recognized biology (a background of epigenetic mutations, most commonly involving RHOA and IDH2, alongside T-cell receptor activation that renders T cells hyperactive), which meaningfully informs treatment selection at relapse.

PTCL-NOS: A Diagnosis of Exclusion, Not an Entity

PTCL-NOS should be understood not as a distinct disease in its own right, but as what remains after ruling out the other recognized categories. The question worth asking a hematopathologist isn't simply "what is this," but specifically which of the recognized entities were ruled out, and with what evidence.

A few specific entities deserve particular attention:

Anaplastic large cell lymphoma (ALCL) is defined in part by ALK status, but critically also requires that CD30 expression be nearly homogeneous — close to 100% of tumor cells, not simply 20-30% positive — before the diagnosis is made. That threshold matters clinically. The ECHELON-2 trial showed improved progression-free and overall survival with brentuximab vedotin plus CHP compared with CHOP, but about 70% of enrolled patients had systemic ALCL, and the trial required only 10% CD30 expression for entry. The remaining subtypes were represented in numbers too small to draw firm conclusions, and subsequent real-world data suggest the benefit outside ALCL is limited at best. In practice the result has been overextrapolated, with brentuximab-CHP sometimes used for tumors showing 5% CD30 positivity — below even the trial's own entry threshold, and well beyond what the data support.

Adult T-cell leukemia/lymphoma (ATLL) cannot reliably be distinguished from PTCL-NOS by histology alone; hematopathologists have told me directly that they need clinical information — hypercalcemia, skin rash, CD25 positivity, and HTLV-1 status — to make this call. The International T-Cell Lymphoma Project quantified this: once HTLV-1 status was known, nearly 40% of cases originally called PTCL-NOS were reclassified as ATLL. Clinical detail as simple as the presence of a rash changed the diagnosis in a small but real fraction of cases. This matters because ATLL carries a substantially different and generally more difficult treatment course, managed on an almost entirely separate pathway from other nodal PTCLs. Geography and travel history alone aren't reliable clues either; in our unpublished institutional experience, about half of our ATLL patients were born in the United States, with no obvious connection to an HTLV-1-endemic region.

Gamma-delta and other cytotoxic T-cell lymphomas, such as hepatosplenic T-cell lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), are aggressive and carry a poor prognosis with conventional chemotherapy alone. For these subtypes I try to move to allogeneic transplant as soon as complete remission is achieved, rather than completing a full standard course of chemotherapy first.

Subtype Should Drive Treatment Selection

Subtype-specific biology should genuinely change management, not just at diagnosis but at relapse. For ALK-negative ALCL, I use autologous transplant in first remission, though the supporting evidence is less definitive than we'd like. ALK-positive ALCL is different — outcomes with chemotherapy alone are good enough that I almost never consolidate with autologous transplant in first remission, reserving it for the occasional patient with very high-risk features. ATLL and hepatosplenic T-cell lymphoma follow a separate path: for those I pursue allogeneic transplant once complete remission is achieved. Biology should also guide relapse therapy: for TFH lymphoma, where an epigenetic mutational background drives disease, I favor epigenetic-targeted approaches (such as hypomethylating agents combined with HDAC inhibitors) over conventional chemotherapy at relapse; for cytotoxic T-cell lymphomas, where JAK-STAT signaling is frequently activated, I've used a JAK inhibitor combined with a PI3K inhibitor; this doublet is in phase I testing and should be pursued on a clinical trial. There is growing interest in more subtype-specific clinical trial eligibility, rather than lumping all "rare" T-cell lymphoma subtypes into a single, poorly-fitting trial design, which has historically made meaningful trial data in these smaller subgroups difficult to generate.

For Patients

Peripheral T-cell lymphoma isn't one disease, it's a family of more than 30 distinct, rare subtypes, and getting the specific subtype right is essential, since treatment differs meaningfully between them.

Because this diagnosis is uncommon and classification systems keep evolving, it's common for an initial diagnosis made outside a specialized center to be revised after expert review, sometimes substantially. This isn't a reflection of poor initial care; it reflects how much additional, specialized testing (detailed immune marker panels, genetic testing, and sometimes viral testing) can be needed to pin down the exact subtype.

If you or a loved one is diagnosed with a T-cell lymphoma, it is worth specifically asking whether the biopsy tissue itself (not just the written pathology report) has been sent for a second opinion at a center with specific expertise in T-cell lymphomas, and whether genetic (next-generation sequencing) and viral (HTLV-1) testing have been completed, since these can meaningfully change both the diagnosis and the treatment plan.

Key Takeaways

  • T-cell lymphomas account for roughly 10-20% of non-Hodgkin lymphoma, with meaningful geographic variation, and comprise more than 30 distinct subtypes.

  • Roughly a quarter of outside T-cell lymphoma diagnoses are discordant on expert review, and in nearly half of those, the correction could change treatment. In international data, about one in eight cases referred as T- or NK-cell lymphoma turned out to be something else entirely.

  • A complete diagnostic workup requires adequate tissue (ideally excisional biopsy), a comprehensive immunophenotype panel, alpha-beta versus gamma-delta lineage assessment, T-cell receptor gene rearrangement for clonality, HTLV-1 testing, and next-generation sequencing.

  • PTCL-NOS is a diagnosis of exclusion, not a distinct disease; the goal should be ruling out each recognized entity with specific evidence, not defaulting to this label when a workup is incomplete.

  • Diagnosing ALCL requires near-homogeneous CD30 expression, close to 100% of tumor cells. ECHELON-2 enrolled at a 10% threshold and was about 70% ALCL, so the survival benefit is best supported in that population — not in tumors with 5% positivity.

  • Adult T-cell leukemia/lymphoma cannot be reliably distinguished from PTCL-NOS by histology alone and requires clinical correlation and HTLV-1 testing; in the International T-Cell Lymphoma Project, knowing HTLV-1 status reclassified nearly 40% of PTCL-NOS cases as ATLL, and it is managed very differently from other nodal PTCLs.

References

  • Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomas (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240.

  • Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720-1748.

  • Sakata-Yanagimoto M, Enami T, Yoshida K, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014;46(2):171-175.

  • Herrera AF, Crosby-Thompson A, Friedberg JW, et al. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014;120(13):1993-1999. doi:10.1002/cncr.28676. PMID 24706502.

  • Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. PMID 18626005.

  • Cairns RA, Iqbal J, Lemonnier F, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901-1903.

  • Horwitz SM, Nirmal AJ, Rahman J, et al. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nat Med. 2024;30(9):2517-2527.

  • Moskowitz A, Ganesan N, Chang T, et al. Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma. Blood. 2024;144(suppl 1):3065.